Capital Markets Day 15 May 2015 Disclaimer This presentation is - - PowerPoint PPT Presentation
Capital Markets Day 15 May 2015 Disclaimer This presentation is - - PowerPoint PPT Presentation
Capital Markets Day 15 May 2015 Disclaimer This presentation is not an offer or solicitation of an offer to buy or sell securities. It is solely for use at this investor meeting and is provided for information only. This presentation does not
This presentation is not an offer or solicitation of an offer to buy or sell securities. It is solely for use at this investor meeting and is provided for information only. This presentation does not contain all the information that is or may be material to a prospective investor (such as risk factors). By attending the presentation or by reading the presentation slides you agree to be bound as follows: This presentation has been prepared by NetScientific plc (the “Company”), is strictly confidential and is not, and should not be construed as, a prospectus or listing particulars relating to the Company. This presentation does not constitute or form part of, and should not be construed as, an offer or invitation to subscribe for, underwrite or otherwise acquire, or a recommendation regarding, any securities of the Company, nor should it or any part of it form the basis of or be relied on in connection with (i) any contract to purchase or subscribe for any securities of the Company, or (ii) any other contract or commitment whatsoever. Nothing in this presentation shall be deemed to be binding against, or to create any obligations or commitment on the part of, any prospective investor or the Company. The contents of this presentation should not be considered to be legal, tax, investment or other advice, and any prospective investor considering the purchase of any securities of the Company should consult with its own counsel and advisers as to all legal, tax, regulatory, financial and related matters concerning an investment in such securities and as to their suitability for such prospective investor. This presentation has been made to you solely for your information and background for discussion purposes only, and may be amended and supplemented and may not be relied upon for the purpose of entering into any transaction. This presentation and its contents are confidential and proprietary to the Company, and no part of it or its subject matter may be reproduced, redistributed, passed on, or the contents otherwise divulged, directly or indirectly, to any other person (excluding the relevant person’s professional advisers) or published in whole or in part for any purpose without the prior written consent of the Company. If this presentation has been received in error it must be returned immediately to the Company. This presentation is not directed to or intended for distribution, or transfer, either directly or indirectly to, or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, transfer, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. In particular, neither this presentation nor any copy hereof may be sent, or taken, transmitted or distributed, directly or indirectly, in or into Australia, Canada, Japan, or the United States (including its territories and dependencies, any state of the United States and the District of Columbia) or to any resident of Australia, Canada or Japan. This presentation is only being provided to persons outside of the United States in reliance on exemptions from the US Securities Act of 1933, as amended (the “Securities Act”). This presentation does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein or offered in connection with this presentation have not been, and will not be, registered under the Securities Act. They may not be offered, sold, transferred, distributed or delivered, directly or indirectly within, into or in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. No public
- ffering of the securities will take place in the United States. Neither the US Securities and Exchange Commission nor any securities regulatory authority of any state or other jurisdiction of the United States has approved or disapproved of an investment in the securities or
passed on the accuracy or adequacy of the contents of this presentation. Any representation to the contrary is a criminal offence in the United States. This communication is directed at (i) persons outside the United Kingdom, or, if this presentation is intended for distribution in the United Kingdom, (ii) solely to (a) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”); (b) members or creditors of a corporate body within the meaning of article 43 of the order; (c) those persons falling within Article 49(2)(a) to (d) of the order; or (d) those persons to whom it can otherwise be distributed without contravention of Article 21 of the Financial Services and Markets Act 2000 or to whom it may otherwise lawfully be distributed (each, a “relevant person”). This presentation must not be acted or relied upon by persons other than relevant persons. Any investment or investment activity to which this communication relates is available only to (i) in the United Kingdom, relevant persons and, (ii) in any member state of the European Economic Area other than the United Kingdom, “qualified investors” within the meaning of article 2(1)(e) of the Prospectus Directive (Directive 2003/71/EC), and will be engaged in only with such persons. This presentation contains forward-looking statements. These statements may include the words “believe”, “expect”, “anticipate”, “intend”, “plan”, “estimate”, “project”, “will”, “may”, “targeting” and similar expressions as well as statements other than statements of historical facts including, without limitation, those regarding the financial position, business strategy, plans, targets and objectives of the management of the Company for future operations (including development plans and objectives). Such forward-looking statements involve known and unknown risks, uncertainties and other important factors which may affect the Company's ability to implement and achieve the economic and monetary policies, budgetary plans, fiscal guidelines and other development benchmarks set out in such forward-looking statements and which may cause actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based
- n numerous assumptions regarding the Company’s present and future policies and plans and the environment in which the Company will operate in the future. Furthermore, certain forward-looking statements are based on assumptions or future events which may not
prove to be accurate. The forward-looking statements in this presentation speak only as of the date of this presentation, and the Company expressly disclaims to the fullest extent permitted by law any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. Nothing in the foregoing is intended to or shall exclude any liability for, or remedy in respect of, fraudulent misrepresentation. The information in this presentation has not been independently verified. No representation or warranty, express or implied, is made as to the fairness, accuracy or completeness of the presentation and the information contained herein and no reliance should be placed on
- it. Information in this presentation (including market data and statistical information) has been obtained from various sources (including third party sources) and the Company does not guarantee the accuracy or completeness of such information. All projections, valuations
and statistical analyses are provided to assist the recipient in the evaluation of matters described herein. They may be based on subjective assessments and assumptions and may use one among alternative methodologies that produce different results and to the extent they are based on historical information, they should not be relied upon as an accurate prediction of future performance. No representation is made as to the reasonableness of the assumptions made within or the accuracy or completeness of any modelling, scenario analysis or back-testing. The information in this presentation is not intended to predict actual results and no assurances are given with respect thereto. None of the Company, its advisers, connected persons or any other person accepts any liability whatsoever for any loss howsoever arising, directly or indirectly, from this presentation or its contents. All information, opinions and estimates contained herein are given as of the date hereof and are subject to change without notice. The financial information referenced in this presentation was derived from financial estimates and/or statements prepared in accordance with accounting principles generally accepted in the United Kingdom (“UK GAAP”). Additionally, for certain entities it has been necessary to pro rate long periods of account to twelve months, whilst other entities (where they have commenced trading during the period) will have shorter periods of account. This may limit the comparability of the financial data with past and future periods. The financial data in this presentation are solely for your information, as background for discussion purposes and may not be relied upon for the purpose of entering into any transaction. The unaudited pro forma financial information set
- ut in this presentation is based on certain important assumptions and adjustments and does not purport to represent what our results of operations actually will be in any future periods.
This presentation does not disclose all the risks and other significant issues related to an investment in any securities of the Company / any transactions referred to herein. In making any investment decision, prospective investors must rely on their own examination of the Company and the terms of any transaction, including the merits and risks involved.
Disclaimer
2
Strategy review and update
Sir Richard Sykes
NetScient NetScientific is a transat ific is a transatlant lantic ic biomed biomedical and heal ical and healthcar hcare technology gr technology group t
- up that funds and
hat funds and builds companies of builds companies offering fering transformat transformative benefits to people’ ive benefits to people’s lives and society ives and society
Transatlantic healthcare investment and commercialisation group Listed on London Stock Exchange in September 2013, raising £30m Led by well qualified senior management team with extensive sector and commercial experience
NetScientific
5
Fund, develop and manage early/mid-stage healthcare technology companies sourced from strategic partnerships and relationships in USA and Europe Primary focus on Digital heal Digital health, Diagnost Diagnostics ics and Therapeut Therapeutics ics Represent highly attractive growth markets where breakthrough technology solutions are in high demand
Investment thesis
6
Team
Experienced entrepreneurial managers
Sir Richard Sykes FRS
Chairman
Sir Richard was previously CEO of Glaxo and Chairman
- f GlaxoSmithKline, Chairman
- f NHS London, Rector of
Imperial College. Currently Chairman of the International Advisory Board, A* Star Biomedical Research Council, Singapore, Chairman of Imperial College Healthcare NHS Trust.
Michael Boyce-Jacino, Ph.D.
Head of US
Heads up the US investments and
- perations. Dr Mike Boyce-Jacino
was CSO of Orchid Biosciences Inc., founding CEO of Bionano Genomics Inc. and Vice President at Beckman Coulter, Inc.
David Gough
Head of Europe
Heads up the European investments and operations. David Gough was formerly Head of Healthcare and Biotechnology at PA Consulting Group, the founder
- f Vectura Group plc and a
healthcare venture capitalist.
François Martelet, M.D
Chief Executive Officer
Joins NetScientific as CEO in June 2015. Medical doctor, previously worked in Eli Lilly, Schering Plough, Novartis, Merck, Avax Technologies and was CEO of Topotarget.
7
Our strategy
Investment strategy
Investing through strategic partnerships
Criteria:
- game-changing platform healthcare technologies
- proof-of-concept achieved
- recipient of non-dilutive funding
- early/mid-stage requiring significant support to grow the business opportunity
Methodology:
- sourcing opportunities from strategic partners who have funded selective transformative companies
- led by dynamic founder entrepreneurs to provide the supervision and drive
- seed funding through convertible note financing/ equity financing
- follow on funding for the most promising opportunities
Differentiation:
- deploying deep sector and commercial experience to build transformative healthcare businesses by providing access to management,
global advisory network and centralised resources
- to maximize shareholder return in the form of capital growth by way of exiting the investments through a trade sale or public listing
9
Investment sources
Wallace H. Coulter Foundation has partnered with sixteen university departments of biomedical
- engineering. Provides non-dilutive
funding for selected projects for commercialisation
WH Coulter Foundation WH Coulter Foundation Thiel Foundation Thiel Foundation Institutions we work with Institutions we work with
Unique sources of opportunities
Peter Thiel’s foundation created Breakout Labs to support companies at the forefront of deep scientific innovation. Provides grant funding to select early-stage companies Long-standing r Long-standing relationships with leading r elationships with leading resear esearchers chers Strategic partnership Strategic partnership
10
Investment model
Accessing highly qualified transformative companies
Investments Investments
Breakthrough companies from leading universities
+ Disruptive technology with str + Disruptive technology with strong IP
- ng IP
+ Entr + Entrepr epreneurial team in place eneurial team in place + Pr + Proof of concept achieved
- of of concept achieved
+ Secur + Secured non-dilutive grant funding ed non-dilutive grant funding
Rigor Rigorous due
- us due
diligence and diligence and selection selection pr process to fund
- cess to fund
the most the most pr promising
- mising
- pportunities
- pportunities
Commer Commercial, cial, clinical and clinical and scientific due scientific due diligence diligence pr process
- cess
Strategic partners Strategic partners
11
Our Port Our Portfol folio has advanced t io has advanced thr hrough
- ugh
incr increased fund eased funding and strategic ing and strategic management into t management into thr hree key sectors ee key sectors includ including significant expansion in ing significant expansion in Digital Heal Digital Health
Delivering actionable information to patients to drive behavioural change Delivering clinical grade data for physicians to drive adoption
DIGITAL HEALTH
Digital Health portfolio
Analytics, Wearables & Smart Devices
WANDA Health
Healthcar Healthcare Intelligence e Intelligence company delivering company delivering clinical grade clinical grade actionable data in actionable data in remote settings emote settings
health
Triventis Health
Digital Health sales Digital Health sales and marketing and marketing company for company formed in med in partnership with partnership with iMPak iMPak Health, a wholly Health, a wholly
- wned subsidiary of
- wned subsidiary of
US hospital gr US hospital group,
- up,
Meridian Health, NJ Meridian Health, NJ
glucosense
Glucosense
Non-invasive glucose Non-invasive glucose monitoring wearable monitoring wearable device for the medical device for the medical and consumer wellness and consumer wellness market market
G-Tech Medical
‘EKG for the gut’ - ‘EKG for the gut’ - Wearable patch earable patch technology for technology for diagnosis and diagnosis and monitoring of monitoring of functional gastric functional gastric disor disorders ders
Neumitra
Wearable devices and earable devices and smart softwar smart software e applications for the applications for the real-time management eal-time management
- f str
- f stress
ess
14
Highly specific tests to provide earlier diagnosis, increased monitoring ability and earlier intervention
DIAGNOSTICS
Diagnostics portfolio
Vortex Biosciences
Circulating Tumor Cell identification, selection and analysis for disease monitoring and personalised therapeutic prescribing
Glycotest
Unique, non-invasive blood tests for liver cancers and fibrosis-cirrhosis
ProAxsis
Respiratory disease diagnosis and treatment monitoring – Cystic Fibrosis and COPD
16
Next generation therapies
THERAPEUTICS
Therapeutics portfolio
PDS Biotechnology
Novel cancer / infectious disease immunotherapeutic drug development company
EpiBone
Regenerative medicine company growing bones from stems cells
Longevity Biotech
Developing new class of therapeutic compounds based on Hybridtides in Metabolic, Neurology, Infectious disease and oncology applications
18
Looking ahead
François Martelet, M.D.
Exciting future
Accelerating companies towards commercialisation Delivering value enhancing news flow across the group
Focus on accelerating five lead companies W Focus on accelerating five lead companies WANDA, V ANDA, Vortex, Glucosense, Glycotest & Pr
- rtex, Glucosense, Glycotest & ProAxsis
- Axsis
Significant news flow in 2015/2016 – expected commercial sales build up in at least two companies WANDA, Vortex Str Strengthen our strategic r engthen our strategic relationships to build a unique focused transfor elationships to build a unique focused transformative portfolio: mative portfolio: Continue to leverage existing relationships (Breakout Labs) to secure ground-breaking technology Establish further strategic partnership in the UK to mirror the partnership with Breakout Labs in the US
20